Nanobiotix (NASDAQ:NBTX) Shares Gap Down – Should You Sell?

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX)’s stock price gapped down before the market opened on Wednesday. The stock had previously closed at $32.87, but opened at $31.45. Nanobiotix shares last traded at $32.7350, with a volume of 4,674 shares trading hands.

Analyst Upgrades and Downgrades

Several research firms have weighed in on NBTX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nanobiotix in a report on Thursday, October 15th. Guggenheim initiated coverage on Nanobiotix in a report on Tuesday, September 15th. They set a “buy” rating and a $64.00 price objective for the company. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $46.67.

Nanobiotix Stock Performance

The stock has a 50-day simple moving average of $30.84 and a two-hundred day simple moving average of $34.05.

About Nanobiotix

Nanobiotix is a French biotechnology company developing nanoparticle-based treatments for cancer. Founded in 2003, the company focuses on using nanomedicine to enhance the effects of established cancer therapies, particularly radiation therapy. Its lead product candidate, NBTXR3, is made from hafnium oxide nanoparticles and is designed to be injected directly into a tumor. When exposed to radiation, the particles are intended to increase damage to cancer cells while limiting the effect on surrounding healthy tissue.